Skip to main content

Relapsed or Refractory Lymphoid Malignancies

2
Pipeline Programs
3
Companies
8
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
1 program
1
BL-M08D1Phase 1
Baili Pharmaceutical
Baili PharmaceuticalChina - Chengdu
1 program
1
BL-M08D1Phase 15 trials
Active Trials
NCT07818499Not Yet Recruiting204Est. Dec 2028
NCT07788950Not Yet Recruiting30Est. Dec 2028
NCT07818486Not Yet Recruiting30Est. Dec 2028
+2 more trials
Mereo BioPharma
Mereo BioPharmaUK - London
1 program
OMP-52M51PHASE_11 trial
Active Trials
NCT01703572Completed24Est. Jan 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Baili PharmaceuticalBL-M08D1
Mereo BioPharmaOMP-52M51

Clinical Trials (8)

Total enrollment: 482 patients across 8 trials

A Study of BL-M08D1 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors

Start: Sep 2026Est. completion: Dec 202830 patients
Phase 2Not Yet Recruiting

A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma

Start: Sep 2026Est. completion: Dec 2028204 patients
Phase 1/2Not Yet Recruiting

A Study of BL-M08D1 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma and Other Solid Tumors

Start: Sep 2026Est. completion: Dec 202830 patients
Phase 1/2Not Yet Recruiting

A Study of BL-M08D1 in Patients With Recurrent or Metastatic Gynecological Malignancies and Other Solid Tumors

Start: Sep 2026Est. completion: Dec 202890 patients
Phase 1/2Not Yet Recruiting

A Study of BL-M08D in Patients With Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors

Start: Sep 2026Est. completion: Dec 202860 patients
Phase 1/2Not Yet Recruiting

A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid Tumors

Start: Feb 2025Est. completion: Jun 202722 patients
Phase 1Recruiting

A Study of BL-M08D1 in Patients With Relapsed or Refractory Lymphoid Malignancies

Start: Jan 2025Est. completion: Dec 202722 patients
Phase 1Recruiting

A Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies

Start: Oct 2012Est. completion: Jan 201624 patients
Phase 1Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 actively recruiting trials targeting 482 patients
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.